Capricor shares plunge 60% to 70% after FDA briefing on Deramiocel

Levi & Korsinsky said it is reviewing potential securities law violations after FDA documents challenged Capricor’s earlier claims of statistically significant cardiac benefits.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.